Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

##STR00001##

An object of the present invention is to provide a photoelectric conversion element that includes a photoelectric conversion film excellent in the vapor deposition suitability, and that exhibits excellent external quantum efficiency to light at all wavelengths in a red wavelength range, a green wavelength range, and a blue wavelength range. Another object of the present invention is to provide an imaging element, an optical sensor, and a compound related to the photoelectric conversion element.

The photoelectric conversion element includes, in the following order, a conductive film, a photoelectric conversion film, and a transparent conductive film, in which the photoelectric conversion film contains a compound represented by Formula (1).

##STR00001##

A polymerizable liquid crystal compound represented by the following general formula (1): ##STR00001##
(the symbols in the general formula (1) are as described in the DESCRIPTION.)

A compound of general formula (1) ##STR00001## [wherein: R.sub.1 and R.sub.2, which are the same or different, each represent a hydrogen atom, a halogen atom, a lower alkyl group, a lower cycloalkyl group, a lower alkanoyl group, a halogen substituted lower alkyl group, a lower alkoxy group, a halogen substituted lower alkoxy group, a cyano group, a cross-linked methylenedioxy group, an ethylenedioxy group, a propylenedioxy group, a lower alkylthio group, a lower alkylsulfonyl group, a carboxyl group, a lower alkoxycarbonyl group, a lower alkylamide group, a lower alkylamino alkylene amide group, an amino group, an alkylamino group, a hydroxy group, a functional group represented by general formula (2), or a functional group represented by general formula (3)
—CONH(CH.sub.2).sub.p—R.sub.3  (2) [wherein R.sub.3 represents a di-lower alkylamino group, a morpholino group, a piperidino group, a 2-methyl-piperidino group, or a 2-oxo-pyrrolidinyl group; p represents an integer from 2 to 6]; ##STR00002## [wherein, R.sub.4 represents a lower alkyl group]; m and n each represent an integer from 0 to 3; the term lower represents a carbon number of 1 to 6; and the halogen atom represents a fluorine, chlorine or bromine atom] can inhibit endoplasmic reticulum stress to a greater extent as compared to known chemical chaperones. The compound thus can be used suitably as an agent for preventing, ameliorating or treating various diseases that are caused by endoplasmic reticulum stress.

The present invention relates to organic light emitting elements, comprising thermally activated delayed fluorescence (TADF) emitters and/or hosts of formula ##STR00001##
which have a sufficiently small energy gap between S.sub.1 and T.sub.1 (ΔE.sub.ST) to enable up-conversion of the triplet exciton from T.sub.1 to S.sub.1. The organic light emitting elements show high electroluminescent efficiency.

The present invention relates to organic light emitting elements, comprising thermally activated delayed fluorescence (TADF) emitters and/or hosts of formula ##STR00001##
which have a sufficiently small energy gap between S.sub.1 and T.sub.1 (ΔE.sub.ST) to enable up-conversion of the triplet exciton from T.sub.1 to S.sub.1. The organic light emitting elements show high electroluminescent efficiency.

Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds. ##STR00001##

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.